D. Helton

发表

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

D. Schoepp, T. Howe, S. M. Massey, 1997, Journal of medicinal chemistry.

2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.

P. Ornstein, D. Schoepp, D D Schoepp, 1998, Journal of medicinal chemistry.

Abstracts from the ASENT 2010 annual meeting March 4–6, 2010

Jeffrey A. Cohen, M. Hallett, C. Toro, 2010, Neurotherapeutics.

LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.

S. Iyengar, D. Gehlert, R. Couture, 1997, The Journal of pharmacology and experimental therapeutics.

General pharmacology of insulin lispro in animals.

T. Jones, M. Kallman, D. Helton, 1996, Arzneimittel-Forschung.

Serotonin‐1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response

K. Rasmussen, M. Kallman, D. Helton, 1997, Synapse.

The proconvulsive activity of quinolone antibiotics in an animal model.

D. Helton, P. Williams, 1991, Toxicology letters.

Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.

D. Schoepp, J. Tizzano, J. Monn, 1998, The Journal of pharmacology and experimental therapeutics.

The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.

K. Rasmussen, D. Helton, J. Berger, 1993, Neuroreport.

Design, Synthesis, and Pharmacological Characterization of (+)-2- Aminobicyclo(3.1.0)hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties.

D. Schoepp, T. Howe, S. M. Massey, 1997 .

The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors

T. Garrett, D. Helton, J. Lucot, 2014, Experimental Brain Research.

Alterations of In‐vitro 5‐HT Receptor Pharmacology as a Function of Multiple Treatment with 5‐Hydroxytryptamine or 8‐Hydroxy‐2‐(di‐N‐propylamino) Tetralin in Rat Isolated Aorta, Uterus and Fundus, and Guinea‐pig Isolated Trachea

D. Helton, Walter E. Colbert, 1994, The Journal of pharmacy and pharmacology.

Central nervous system characterization of the new cholecystokininB antagonist LY288513

K. Rasmussen, M. Kallman, D. Helton, 1996, Pharmacology Biochemistry and Behavior.

General pharmacology of gemcitabine hydrochloride in animals.

R. Heim, G. Rush, D. Helton, 1994, Arzneimittel-Forschung.

LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats

D. Schoepp, J. Tizzano, J. Monn, 1997, Neuropharmacology.

Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists

D. Schoepp, A. Fix, J. Tizzano, 1993, Neuroscience Letters.

The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors

T. Garrett, D. Helton, J. Lucot, 2014, Experimental Brain Research.

Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity

K. Rasmussen, J. Tizzano, D. Helton, 2005, Psychopharmacology.